GLP-3 (20mg)

Retatrutide is a triple agonist peptide targeting GIP, GLP-1, and glucagon receptors. Research suggests potential benefits for weight management, metabolic health, and glucose regulation. This novel peptide demonstrates promising results in preclinical studies for addressing metabolic syndrome and obesity-related complications.